Ozempic and Soliqua Comparison

Ozempic®(semaglutide)	Soliqua ®(insulin glargine / lixisenatide)
Prescription Only Ozempic (semaglutide) is a once-weekly injection that helps improve blood sugar levels in adults with type 2 diabetes mellitus. It also reduces the risk of major cardiovascular...	Prescription Only Soliqua 100/33 is a combination medication featuring insulin glargine and lixisenatide. Insulin glargine offers prolonged blood glucose reduction, while lixisenatide enhances...
Administration
Subcutaneous. Learn more.	Subcutaneous. Learn more.
Dosing
0.25 mg SC injection q/week for 4 weeks. After 4 weeks, increase to 0.5 mg SC q/week. • If more control needed after 4 weeks on 0.5 mg, increase to 1 mg SC q/week • If further control needed after 4 weeks on 1 mg, increase to 2 mg SC q/week (max dose). . Learn more.	Administer SOLIQUA 100/33 subcutaneously once a day within the hour prior to the first meal of the day. See starting dose and titration table in the PI for schedule.. Learn more.
Latin Shorthand
0.25 mg SC injection q/week for 4 weeks. After 4 weeks, increase to 0.5 mg SC q/week. • If more control needed after 4 weeks on 0.5 mg, increase to 1 mg SC q/week • If further control needed after 4 weeks on 1 mg, increase to 2 mg SC q/week (max dose). . Learn more.	Administer SOLIQUA 100/33 SC qd within the hour prior to the first meal of the day. See starting dose and titration table in the PI for schedule.. Learn more.
Out-Of-Pocket Costs With Copay Card
$25. Learn more.	$9. Learn more.
Annual Cap
$150 for 1 month supply; $300 for 2 month supply; $450 for 3 month supply. Learn more.	$365 per pack. Learn more.
Assistance Expiration
24 months. Learn more.	12 months. Learn more.
Generics
No lower-cost generic available	No lower-cost generic available
Adverse Reactions
The most common adverse reactions, reported in ≥5% of patients treated with OZEMPIC® are: nausea, vomiting, diarrhea, abdominal pain and constipation.. Learn more.	The most common adverse reactions, reported in ≥5% of patients treated with SOLIQUA 100/33 include hypoglycemia, nausea, nasopharyngitis, diarrhea, upper respiratory tract infection, and headache.. Learn more.
Mechanism of Actions (MoA)
GLP-1 Receptor Agonists. Learn more.	GLP-1 Receptor Agonists. Learn more.
Special Populations
What is the risk of using OZEMPIC® during pregnancy? Limited data exist on the use of semaglutide in pregnant women, making it challenging to determine the potential drug-associated risk for adverse developmental outcomes. Poorly controlled diabetes during pregnancy poses risks for both the mother and fetus. OZEMPIC® should be used during pregnancy only if the potential benefits outweigh the potential risks. What are the potential risks to the fetus from exposure to semaglutide during pregnancy? Based on animal studies, there may be potential risks to the fetus from exposure to semaglutide during pregnancy. In pregnant rats, exposure to semaglutide during organogenesis led to embryofetal mortality, structural abnormalities, and growth alterations. Similar findings were observed in rabbits and cynomolgus monkeys. What is the estimated background risk of birth defects and miscarriage in pregnant women? In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. For women with pre-gestational diabetes, the estimated background risk of major birth defects is 6 to 10% with a peri-conceptional HbA1c >7 and can be as high as 20 to 25% with a peri-conceptional HbA1c >10. What are the disease-associated risks for pregnant women with poorly controlled diabetes? Poorly controlled diabetes during pregnancy increases the risk of hypoglycemia, hyperglycemia, diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, and delivery complications. It also increases the fetal risk for major birth defects, stillbirth, and macrosomia-related morbidity. What do the animal data reveal about the effects of semaglutide exposure during pregnancy? Animal data indicate that exposure to semaglutide during pregnancy in rats, rabbits, and cynomolgus monkeys can result in embryofetal mortality, structural abnormalities, and alterations in growth. These effects were observed at various dose levels and exposures in different animal species. What is known about semaglutide exposure during lactation? There is no information available regarding the presence of semaglutide in human milk or its effects on breastfed infants or milk production. Semaglutide was detected in the milk of lactating rats, but the clinical relevance of these findings is not clear. Should OZEMPIC® be discontinued in women planning a pregnancy? OZEMPIC® should be discontinued in women at least 2 months before planning a pregnancy due to the long washout period required for semaglutide. Is OZEMPIC® safe for pediatric use? Safety and efficacy of OZEMPIC® have not been established in pediatric patients (younger than 18 years). Is OZEMPIC® safe for geriatric use? No overall differences in safety or efficacy have been detected between older and younger patients in clinical trials. However, caution should be exercised in geriatric patients. Is OZEMPIC® safe for patients with renal impairment? No dose adjustment of OZEMPIC® is recommended for patients with renal impairment. Semaglutide pharmacokinetics have not shown clinically relevant changes in subjects with renal impairment, including end-stage renal disease. Is OZEMPIC® safe for patients with hepatic impairment? No dose adjustment of OZEMPIC® is recommended for patients with hepatic impairment. Semaglutide pharmacokinetics have not shown clinically relevant changes in subjects with varying degrees of hepatic impairment.	1. What are the pregnancy risks associated with SOLIQUA 100/33? Based on animal studies, there may be fetal risks from exposure to lixisenatide during pregnancy. SOLIQUA 100/33 should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Limited data are available, and there is no clear association with major birth defects or miscarriage risk. 2. What is the risk of major birth defects and miscarriage in pregnant women with diabetes? The estimated background risk of major birth defects is 6%–10% in women with pregestational diabetes and HbA1c >7, and it can be as high as 20%–25% with HbA1c >10. The background risk of miscarriage for this population is unknown. In the general U.S. population, the estimated background risk of major birth defects and miscarriage is 2%–4% and 15%–20%, respectively. 3. What are the maternal and fetal risks associated with poorly controlled diabetes during pregnancy? Poorly controlled diabetes during pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, and delivery complications. The fetal risk includes major birth defects, stillbirth, and macrosomia-related morbidity. 4. What fetal risks are associated with lixisenatide exposure during pregnancy? Lixisenatide exposure in pregnant rats and rabbits was associated with visceral closure and skeletal defects. These effects were observed at exposures higher than the highest clinical dose. Decreases in maternal food intake and weight gain were also observed. However, the relevance of these findings to human risk assessment is confounded by concurrent maternal effects. 5. Is there any information about lixisenatide and insulin glargine in human milk? There is no information about the presence of lixisenatide and insulin glargine in human milk, their effects on the breastfed infant, or their effects on milk production. Lixisenatide is present in rat milk. 6. Is SOLIQUA 100/33 safe and effective for pediatric patients? Safety and effectiveness of SOLIQUA 100/33 have not been established in pediatric patients. 7. What should be considered for geriatric patients using SOLIQUA 100/33? While no overall differences in effectiveness and safety were observed in geriatric patients, caution should be exercised. In elderly patients with diabetes, dosing should be conservative to avoid hypoglycemic reactions, as hypoglycemia may be difficult to recognize in the elderly. 8. What are the considerations for patients with renal impairment using SOLIQUA 100/33? Frequent glucose monitoring and dose adjustment may be necessary for SOLIQUA 100/33 in patients with renal impairment. Patients with severe renal impairment should be closely monitored for adverse reactions and changes in renal function. 9. How does hepatic impairment affect the use of SOLIQUA 100/33? The effect of hepatic impairment on the pharmacokinetics of SOLIQUA 100/33 has not been studied. Frequent glucose monitoring and dose adjustment may be necessary for patients with hepatic impairment. 10. Can SOLIQUA 100/33 be used in patients with gastroparesis? SOLIQUA 100/33 is not recommended for patients with severe gastroparesis. Lixisenatide, a component of SOLIQUA 100/33, slows gastric emptying.

Ozempic®(semaglutide)

Soliqua ®(insulin glargine / lixisenatide)

Prescription Only

Ozempic (semaglutide) is a once-weekly injection that helps improve blood sugar levels in adults with type 2 diabetes mellitus. It also reduces the risk of major cardiovascular...

Prescription Only

Soliqua 100/33 is a combination medication featuring insulin glargine and lixisenatide. Insulin glargine offers prolonged blood glucose reduction, while lixisenatide enhances...

Dosage & Administration

Administration

Subcutaneous. Learn more.

Dosing

0.25 mg SC injection q/week for 4 weeks. After 4 weeks, increase to 0.5 mg SC q/week. • If more control needed after 4 weeks on 0.5 mg, increase to 1 mg SC q/week • If further control needed after 4 weeks on 1 mg, increase to 2 mg SC q/week (max dose). . Learn more.

Administer SOLIQUA 100/33 subcutaneously once a day within the hour prior to the first meal of the day. See starting dose and titration table in the PI for schedule.. Learn more.

Latin Shorthand

Administer SOLIQUA 100/33 SC qd within the hour prior to the first meal of the day. See starting dose and titration table in the PI for schedule.. Learn more.

Financial Assistance

Out-Of-Pocket Costs With Copay Card

$25. Learn more.

$9. Learn more.

Annual Cap

$150 for 1 month supply; $300 for 2 month supply; $450 for 3 month supply. Learn more.

$365 per pack. Learn more.

Assistance Expiration

24 months. Learn more.

12 months. Learn more.

Generics

No lower-cost generic available

Physician Advisory

Adverse Reactions

The most common adverse reactions, reported in ≥5% of patients treated with OZEMPIC® are: nausea, vomiting, diarrhea, abdominal pain and constipation.. Learn more.

The most common adverse reactions, reported in ≥5% of patients treated with SOLIQUA 100/33 include hypoglycemia, nausea, nasopharyngitis, diarrhea, upper respiratory tract infection, and headache.. Learn more.

Mechanism of Actions (MoA)

GLP-1 Receptor Agonists. Learn more.

Special Populations

What is the risk of using OZEMPIC® during pregnancy?

Limited data exist on the use of semaglutide in pregnant women, making it challenging to determine the potential drug-associated risk for adverse developmental outcomes. Poorly controlled diabetes during pregnancy poses risks for both the mother and fetus. OZEMPIC® should be used during pregnancy only if the potential benefits outweigh the potential risks.

What are the potential risks to the fetus from exposure to semaglutide during pregnancy?

Based on animal studies, there may be potential risks to the fetus from exposure to semaglutide during pregnancy. In pregnant rats, exposure to semaglutide during organogenesis led to embryofetal mortality, structural abnormalities, and growth alterations. Similar findings were observed in rabbits and cynomolgus monkeys.

What is the estimated background risk of birth defects and miscarriage in pregnant women?

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. For women with pre-gestational diabetes, the estimated background risk of major birth defects is 6 to 10% with a peri-conceptional HbA1c >7 and can be as high as 20 to 25% with a peri-conceptional HbA1c >10.

What are the disease-associated risks for pregnant women with poorly controlled diabetes?

Poorly controlled diabetes during pregnancy increases the risk of hypoglycemia, hyperglycemia, diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, and delivery complications. It also increases the fetal risk for major birth defects, stillbirth, and macrosomia-related morbidity.

What do the animal data reveal about the effects of semaglutide exposure during pregnancy?

Animal data indicate that exposure to semaglutide during pregnancy in rats, rabbits, and cynomolgus monkeys can result in embryofetal mortality, structural abnormalities, and alterations in growth. These effects were observed at various dose levels and exposures in different animal species.

What is known about semaglutide exposure during lactation?

There is no information available regarding the presence of semaglutide in human milk or its effects on breastfed infants or milk production. Semaglutide was detected in the milk of lactating rats, but the clinical relevance of these findings is not clear.

Should OZEMPIC® be discontinued in women planning a pregnancy?

OZEMPIC® should be discontinued in women at least 2 months before planning a pregnancy due to the long washout period required for semaglutide.

Is OZEMPIC® safe for pediatric use?

Safety and efficacy of OZEMPIC® have not been established in pediatric patients (younger than 18 years).

Is OZEMPIC® safe for geriatric use?

No overall differences in safety or efficacy have been detected between older and younger patients in clinical trials. However, caution should be exercised in geriatric patients.

Is OZEMPIC® safe for patients with renal impairment?

No dose adjustment of OZEMPIC® is recommended for patients with renal impairment. Semaglutide pharmacokinetics have not shown clinically relevant changes in subjects with renal impairment, including end-stage renal disease.

Is OZEMPIC® safe for patients with hepatic impairment?

No dose adjustment of OZEMPIC® is recommended for patients with hepatic impairment. Semaglutide pharmacokinetics have not shown clinically relevant changes in subjects with varying degrees of hepatic impairment.

1. What are the pregnancy risks associated with SOLIQUA 100/33?

Based on animal studies, there may be fetal risks from exposure to lixisenatide during pregnancy. SOLIQUA 100/33 should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Limited data are available, and there is no clear association with major birth defects or miscarriage risk.

2. What is the risk of major birth defects and miscarriage in pregnant women with diabetes?

The estimated background risk of major birth defects is 6%–10% in women with pregestational diabetes and HbA1c >7, and it can be as high as 20%–25% with HbA1c >10. The background risk of miscarriage for this population is unknown. In the general U.S. population, the estimated background risk of major birth defects and miscarriage is 2%–4% and 15%–20%, respectively.

3. What are the maternal and fetal risks associated with poorly controlled diabetes during pregnancy?

Poorly controlled diabetes during pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, and delivery complications. The fetal risk includes major birth defects, stillbirth, and macrosomia-related morbidity.

4. What fetal risks are associated with lixisenatide exposure during pregnancy?

Lixisenatide exposure in pregnant rats and rabbits was associated with visceral closure and skeletal defects. These effects were observed at exposures higher than the highest clinical dose. Decreases in maternal food intake and weight gain were also observed. However, the relevance of these findings to human risk assessment is confounded by concurrent maternal effects.

5. Is there any information about lixisenatide and insulin glargine in human milk?

There is no information about the presence of lixisenatide and insulin glargine in human milk, their effects on the breastfed infant, or their effects on milk production. Lixisenatide is present in rat milk.

6. Is SOLIQUA 100/33 safe and effective for pediatric patients?

Safety and effectiveness of SOLIQUA 100/33 have not been established in pediatric patients.

7. What should be considered for geriatric patients using SOLIQUA 100/33?

While no overall differences in effectiveness and safety were observed in geriatric patients, caution should be exercised. In elderly patients with diabetes, dosing should be conservative to avoid hypoglycemic reactions, as hypoglycemia may be difficult to recognize in the elderly.

8. What are the considerations for patients with renal impairment using SOLIQUA 100/33?

Frequent glucose monitoring and dose adjustment may be necessary for SOLIQUA 100/33 in patients with renal impairment. Patients with severe renal impairment should be closely monitored for adverse reactions and changes in renal function.

9. How does hepatic impairment affect the use of SOLIQUA 100/33?

The effect of hepatic impairment on the pharmacokinetics of SOLIQUA 100/33 has not been studied. Frequent glucose monitoring and dose adjustment may be necessary for patients with hepatic impairment.

10. Can SOLIQUA 100/33 be used in patients with gastroparesis?

SOLIQUA 100/33 is not recommended for patients with severe gastroparesis. Lixisenatide, a component of SOLIQUA 100/33, slows gastric emptying.

Ozempic® Alternatives